Jonathan Zalevsky Sells 3,867 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the transaction, the insider directly owned 21,354 shares in the company, valued at $761,697.18. This trade represents a 15.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The stock was sold at an average price of $54.28, for a total transaction of $62,801.96.

Nektar Therapeutics Stock Up 1.6%

Nektar Therapeutics stock opened at $37.11 on Friday. Nektar Therapeutics has a twelve month low of $6.45 and a twelve month high of $66.92. The firm has a 50 day moving average price of $48.45 and a 200-day moving average price of $44.49. The company has a market capitalization of $754.82 million, a P/E ratio of -4.66 and a beta of 1.31.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) EPS for the quarter, topping analysts’ consensus estimates of ($2.85) by $1.00. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. The company had revenue of $11.79 million for the quarter, compared to analysts’ expectations of $10.20 million. Equities analysts expect that Nektar Therapeutics will post -0.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on NKTR. BTIG Research lifted their price objective on Nektar Therapeutics from $100.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Citigroup initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, November 26th. They issued a “buy” rating and a $102.00 target price for the company. Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. HC Wainwright raised their price objective on shares of Nektar Therapeutics from $120.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a report on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.83.

Institutional Trading of Nektar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 210 shares during the period. FNY Investment Advisers LLC purchased a new stake in shares of Nektar Therapeutics in the second quarter worth $39,000. Compass Wealth Management LLC bought a new stake in Nektar Therapeutics during the third quarter valued at $88,000. Bessemer Group Inc. boosted its stake in Nektar Therapeutics by 1,741.2% during the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 1,480 shares during the period. Finally, Bayforest Capital Ltd purchased a new position in Nektar Therapeutics during the third quarter worth about $96,000. Institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.